Business Description
Lexicon Pharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US5288723027
Share Class Description:
LXRX: Ordinary SharesTotal Employee Number:
81Description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.96 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.28 | |||||
Debt-to-EBITDA | -3.31 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -0.38 | |||||
Beneish M-Score | -1.29 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 415.5 | |||||
3-Year EBITDA Growth Rate | 42.4 | |||||
3-Year EPS without NRI Growth Rate | 39.1 | |||||
3-Year FCF Growth Rate | 29.9 | |||||
3-Year Book Growth Rate | -21.9 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.36 | |||||
9-Day RSI | 52.99 | |||||
14-Day RSI | 53.83 | |||||
3-1 Month Momentum % | 28.57 | |||||
6-1 Month Momentum % | 27.06 | |||||
12-1 Month Momentum % | 78.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 18.79 | |||||
Quick Ratio | 18.77 | |||||
Cash Ratio | 17.24 | |||||
Days Inventory | 224.81 | |||||
Days Sales Outstanding | 69.31 | |||||
Days Payable | 5488.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.4 | |||||
Shareholder Yield % | -2.53 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.5 | |||||
Operating Margin % | -34.79 | |||||
Net Margin % | -37.46 | |||||
EBITDA Margin % | -25.04 | |||||
FCF Margin % | -55.72 | |||||
OCF Margin % | -55.72 | |||||
ROE % | -19.1 | |||||
ROA % | -11.03 | |||||
ROIC % | -22.88 | |||||
3-Year ROIIC % | 156.22 | |||||
ROC (Joel Greenblatt) % | -186.66 | |||||
ROCE % | -9.14 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 12.39 | |||||
PB Ratio | 4.81 | |||||
Price-to-Tangible-Book | 6.23 | |||||
EV-to-EBIT | -50.62 | |||||
EV-to-Forward-EBIT | -14.51 | |||||
EV-to-EBITDA | -52.23 | |||||
EV-to-Forward-EBITDA | -14.51 | |||||
EV-to-Revenue | 13.08 | |||||
EV-to-Forward-Revenue | 20.33 | |||||
EV-to-FCF | -23.48 | |||||
| Price-to-Net-Current-Asset-Value | 8.23 | |||||
| Price-to-Net-Cash | 9.22 | |||||
Earnings Yield (Greenblatt) % | -1.98 | |||||
FCF Yield % | -3.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LXRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lexicon Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 69.643 | ||
| EPS (TTM) ($) | -0.07 | ||
| Beta | 1.1186 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 0.69 | ||
| Volatility % | 49.44 | ||
| 14-Day RSI | 53.83 | ||
| 14-Day ATR ($) | 0.146083 | ||
| 20-Day SMA ($) | 2.31775 | ||
| 12-1 Month Momentum % | 78.51 | ||
| 52-Week Range ($) | 1 - 2.68 | ||
| Shares Outstanding (Mil) | 444.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lexicon Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lexicon Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 106 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 105 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | In 14 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 13 days | ||
| Jefferies Global Healthcare Conference | 2026-06-04 14:00 | 1.85 (+0.54%) | ||
| 4th Annual H.C. Wainwright BioConnect Investor Conference | 2026-05-19 16:30 | 2.14 (-3.60%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 08:30 | 1.60 (-3.61%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 1.60 (-3.61%) | ||
| General meeting for 2026 | 2026-04-30 08:00 | 1.55 (-6.06%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 08:30 | 1.63 (+0.31%) |
Show
Entries
Lexicon Pharmaceuticals Inc Frequently Asked Questions
What is Lexicon Pharmaceuticals Inc(LXRX)'s stock price today?
The current price of LXRX is $2.31. The 52 week high of LXRX is $2.68 and 52 week low is $1.00.
When is next earnings date of Lexicon Pharmaceuticals Inc(LXRX)?
The next earnings date of Lexicon Pharmaceuticals Inc(LXRX) is 2026-08-06 Est..
Does Lexicon Pharmaceuticals Inc(LXRX) pay dividends? If so, how much?
Lexicon Pharmaceuticals Inc(LXRX) does not pay dividend.
Guru Commentaries on NAS:LXRX
No articles.
Press Release
Articles on Lexicon Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers